Hello, everyone. And how are you today? Yet another pile of snow has descended on the Pharmalot corporate campus, where we have a shovel in one hand and a cup of stimulation in the other. Nonetheless, we will not be deterred from foraging for interesting news and assorted developments. And so here are a few tidbits to get us all started. Enjoy, and we hope your day goes well...
AstraZeneca To Double Stock Buybacks Amid Drug Setbacks (Bloomberg News)
Lilly Profit And Sales Beat Wall Street Forecasts (Reuters)
Off-Label Prescribing To Children Is Widespread In Europe (PharmaTimes)
FDA Denies Additional Indication For Glaxo's Avodart (Reuters)
Data Exclusivity Remains Hurdle To EU-India Free Trade Deal (Business Standard)
Novartis Profit Falls And Vaccine Sales Slide (Bloomberg News)
Amylin Will Resubmit Bydureon For Approval Later This Year (Reuters)
Kentucky Judge Denies AstraZeneca Bid For New Trial (Associated Press)
FDA Panel Backs Wider Use Of Abbott Stent (Associated Press)
pic thx to nicole/mealy monster flickr